Eric Raefsky

1.1k total citations
46 papers, 835 citations indexed

About

Eric Raefsky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eric Raefsky has authored 46 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Eric Raefsky's work include Cancer Treatment and Pharmacology (16 papers), Lung Cancer Research Studies (10 papers) and Breast Cancer Treatment Studies (8 papers). Eric Raefsky is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Lung Cancer Research Studies (10 papers) and Breast Cancer Treatment Studies (8 papers). Eric Raefsky collaborates with scholars based in United States and United Kingdom. Eric Raefsky's co-authors include John D. Hainsworth, Neal S. Young, F. Anthony Greco, Nicholas Zoumbos, Leonidas C. Platanias, David R. Spigel, Howard A. Burris, Denise A. Yardley, N. W. Peacock and C. Farley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Eric Raefsky

45 papers receiving 808 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Raefsky United States 14 396 244 195 158 137 46 835
Martin D. Phillips United States 12 349 0.9× 275 1.1× 192 1.0× 153 1.0× 144 1.1× 16 978
M. Testi Italy 19 244 0.6× 296 1.2× 183 0.9× 289 1.8× 174 1.3× 62 983
Su S. Chen United States 13 623 1.6× 405 1.7× 195 1.0× 162 1.0× 80 0.6× 18 1.0k
­Mahesh Seetharam United States 15 408 1.0× 286 1.2× 261 1.3× 276 1.7× 162 1.2× 62 922
H.‐G. Mergenthaler Germany 12 543 1.4× 212 0.9× 95 0.5× 111 0.7× 68 0.5× 33 903
Leonard M. Klein United States 14 432 1.1× 134 0.5× 205 1.1× 220 1.4× 128 0.9× 49 834
Daniel Oruzio Germany 14 426 1.1× 149 0.6× 104 0.5× 89 0.6× 62 0.5× 30 658
I Tepler United States 11 681 1.7× 151 0.6× 332 1.7× 217 1.4× 136 1.0× 19 1.1k
S. Hegewisch-Becker Germany 20 665 1.7× 395 1.6× 156 0.8× 215 1.4× 87 0.6× 40 1.1k
Anna Novarino Italy 19 577 1.5× 111 0.5× 197 1.0× 294 1.9× 319 2.3× 43 1.1k

Countries citing papers authored by Eric Raefsky

Since Specialization
Citations

This map shows the geographic impact of Eric Raefsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Raefsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Raefsky more than expected).

Fields of papers citing papers by Eric Raefsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Raefsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Raefsky. The network helps show where Eric Raefsky may publish in the future.

Co-authorship network of co-authors of Eric Raefsky

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Raefsky. A scholar is included among the top collaborators of Eric Raefsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Raefsky. Eric Raefsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yardley, Denise A., et al.. (2014). Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial. Breast Cancer Research and Treatment. 148(3). 535–540. 1 indexed citations
2.
Hainsworth, John D., F. Anthony Greco, Eric Raefsky, et al.. (2014). Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 14(4). 277–283. 18 indexed citations
3.
Yardley, Denise A., Eric Raefsky, Dana S. Thompson, et al.. (2011). Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer. Clinical Breast Cancer. 11(5). 297–305. 42 indexed citations
4.
Raefsky, Eric, David R. Spigel, J. R. Infante, et al.. (2011). Phase II study of NK012 in relapsed small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). 7079–7079. 12 indexed citations
5.
Yardley, Denise A., Howard A. Burris, N. W. Peacock, et al.. (2010). A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment. 123(2). 471–475. 21 indexed citations
6.
Flinn, Ian W., Eric Raefsky, Ralph V. Boccia, et al.. (2010). Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients. Blood. 116(21). 4015–4015. 7 indexed citations
7.
Hainsworth, John D., David R. Spigel, Eric Raefsky, et al.. (2008). Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first‐line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Cancer. 112(6). 1288–1295. 28 indexed citations
8.
Raefsky, Eric, Dana S. Thompson, Chun Meng, et al.. (2008). Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer. Journal of Clinical Oncology. 26(15_suppl). 627–627. 11 indexed citations
9.
Jones, Suzanne F., John G. Kuhn, F. Anthony Greco, et al.. (2005). A Phase I/II Study of Exisulind in Combination with Docetaxel/Carboplatin in Patients with Metastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 6(6). 361–366. 12 indexed citations
10.
Hainsworth, John D., David R. Spigel, Eric Raefsky, et al.. (2005). Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site. Cancer. 104(9). 1992–1997. 25 indexed citations
11.
Jones, Suzanne F., F. Anthony Greco, Victor G. Gian, et al.. (2005). A phase I trial of protracted oral fixed‐dose temozolomide. Cancer. 104(9). 1985–1991. 3 indexed citations
12.
Meluch, Anthony A., F. Anthony Greco, Lisa H. Morrissey, et al.. (2003). Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone‐refractory prostate carcinoma. Cancer. 98(10). 2192–2198. 8 indexed citations
13.
Hainsworth, John D., Howard A. Burris, Dana S. Thompson, et al.. (2002). Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies. Investigational New Drugs. 20(1). 55–61. 15 indexed citations
14.
Greco, F. Anthony, Howard A. Burris, James R. Gray, et al.. (2001). Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma. Cancer. 92(8). 2142–2147. 7 indexed citations
15.
Schwartzberg, Lee S., Robert Birch, Kurt W. Tauer, et al.. (1999). Adjuvant Dose-Intense Chemotherapy With Peripheral Blood Stem Cell Support in Stage II-III Breast Cancer With Five to Nine Involved Axillary Lymph Nodes. American Journal of Clinical Oncology. 22(2). 136–142. 3 indexed citations
16.
Schwartzberg, Lee S., Robert Samuel Birch, William H. West, et al.. (1998). Sequential Treatment Including High-Dose Chemotherapy With Peripheral Blood Stem Cell Support in Patients With High-Risk Stage II-III Breast Cancer. American Journal of Clinical Oncology. 21(5). 523–531. 8 indexed citations
17.
18.
Raefsky, Eric, et al.. (1989). Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. British Journal of Haematology. 72(2). 278–284. 75 indexed citations
19.
Wong, P., Sung Won Chung, Eric Raefsky, Connie J. Eaves, & Arthur W. Nienhuis. (1988). Blast colonies containing hemopoietic progenitor cells can give rise to Abelson virus (A-MuLV)-transformed cell lines.. PubMed. 16(1). 5–11. 5 indexed citations
20.
Zoumbos, Nicholas, Eric Raefsky, & NS Young. (1986). Lymphokines and hematopoiesis.. PubMed. 14. 201–27. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin D. Phillips Breakdown of academic impact, for papers by M. Testi Breakdown of academic impact, for papers by Su S. Chen Breakdown of academic impact, for papers by ­Mahesh Seetharam Breakdown of academic impact, for papers by H.‐G. Mergenthaler Breakdown of academic impact, for papers by Leonard M. Klein Breakdown of academic impact, for papers by Daniel Oruzio Breakdown of academic impact, for papers by I Tepler Breakdown of academic impact, for papers by S. Hegewisch-Becker Breakdown of academic impact, for papers by Anna Novarino
Rankless by CCL
2026